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Abstract
Archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) is a safe mucosal adjuvant that elicits long lasting and
memory boostable mucosal and systemic immune responses to model antigens such as ovalbumin. In this study, we
evaluated the potential of the AMVAD system for eliciting protective immunity against mucosal bacterial infections, using a
mouse model of intranasal Francisella tularensis LVS (LVS) challenge. Intranasal immunization of mice with cell free extract of
LVS (LVSCE) adjuvanted with the AMVAD system (LVSCE/AMVAD) induced F. tularensis-specific antibody responses in sera
and bronchoalveolar lavage fluids, as well as antigen-specific splenocyte proliferation and IL-17 production. More
importantly, the AMVAD vaccine partially protected the mice against a lethal intranasal challenge with LVS. Compared to
LVSCE immunized and naı ¨ve mice, the LVSCE/AMVAD immunized mice showed substantial to significant reduction in
pathogen burdens in the lungs and spleens, reduced serum and pulmonary levels of proinflammatory cytokines/
chemokines, and longer mean time to death as well as significantly higher survival rates (p,0.05). These results suggest that
the AMVAD system is a promising mucosal adjuvant and vaccine delivery technology, and should be explored further for its
applications in combating mucosal infectious diseases.
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Introduction
Many microbial pathogens invade their human and animal
hosts through the mucosal surfaces of the respiratory, gastrointes-
tinal and urogenital tracts [1,2]. Immunity at the mucosal surface
would help prevent the pathogen from establishing and from
disseminating to other organs to cause systemic disease. The
majority of currently approved human/veterinary vaccines are
administered systemically, and they fail to elicit effective mucosal
immunity [2,3,4]. The few mucosal vaccines currently in the
marketplace are all based on the use of live-attenuated or dead
pathogen cells [3,5,6,7]. Although these vaccines are efficacious,
there are lingering concerns regarding potential reversion to
virulence, overall safety in immunocompromised populations
[3,8,9], and the possible inclusion of toxic cell components such
as endotoxins [10]. Vaccines based on acellular or subunit
antigens would be safer, but such antigens are generally poorly
immunogenic on their own [3,10,11]. This has sustained global
research efforts at developing mucosal adjuvants and non-
replicating delivery systems such as detoxified cholera toxin (CT)
and Escherichia coli heat labile toxin, CpG oligonucleotides, DNA,
microparticulates such as virosomes, liposomes, cochleates,
polymeric microspheres, and immunostimulating complexes such
as ISCOMs [8,9,11,12].
We recently demonstrated that intranasal (i.n.) immunization of
mice with ovalbumin (OVA) formulated in archaeal lipid mucosal
vaccine adjuvant and delivery (AMVAD) structures prepared from
the total polar lipids extract (TPL) of Methanobrevibacter smithii
(OVA/AMVAD), or other archaeal species, elicited strong anti-
OVA IgA responses at both local (nasal) and distal (gastrointestinal
and vaginal) sites, and in sera [13]. Additionally, robust, antigen-
specific systemic antibody (serum IgG1 and IgG2a) and CD8
+
CTL responses were also generated. The mucosal and systemic
responses elicited were generally well sustained over time, and
exhibited strong memory boost responses. Detailed toxicity
evaluation in mice demonstrated an excellent safety profile for
the AMVAD system at an i.n. dose that was 10-fold greater than
that required for vaccine efficacy [14]. These results suggested that
the AMVAD system represents a promising technology for
mucosal vaccine development. However, the potential of the
AMVAD system in eliciting protection against an infectious
challenge had not been evaluated to-date.
In the current study, using a mouse model of i.n. challenge with
Francisella tularensis live vaccine strain (LVS), we show that the
AMVAD based vaccine induced antigen-specific cellular and
humoral immune responses, reduced the tissue pathogen burdens,
and enhanced the survival of the challenged mice, compared to
the naı ¨ve mice or the mice immunized with the antigen alone.
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Total polar lipids extract
The archaeal species Methanobrevibacter smithii ALI (DSM 2375)
was grown in a 75 L fermenter vessel as described previously [15].
The total polar lipids extract (TPL) was obtained from the biomass
by solvent extraction [16]. The TPL was analyzed by FAB MS
and thin layer chromatography for quality control purposes and
was stored in chloroform, at 4uC to minimize solvent evaporation.
Francisella tularensis LVS cell free extract (LVSCE) antigen
preparation
Francisella tularensis LVS (ATCC 29684) cells grown on 40 plates
of cysteine heart agar supplemented with 1% wt/vol haemoglobin
and 1% vol/vol of Isovitalex
R enrichment (Beckton and
Dickinson, Sparks, MD, USA) were harvested, washed, and re-
suspended into 160 ml of saline (0.85% NaCl, autoclaved 121uC
for 15 min). The cells were lysed by two successive passages
(68,900–103,350 KPa) through an Emulsiflex
R-C5 high pressure
homogenizer (Avestin Inc., Ottawa, Ontario, Canada). The lysate
was centrifuged at 16,0006g for 90 min, the supernatant
containing the cell-free extract (LVSCE) was filtered through
0.22 mm filters, and an aliquot was plated on cysteine heart agar to
verify absence of viable cells. The total protein content of the
LVSCE was 4.46 mg/ml by Lowry assay, using bovine serum
albumin as the standard, and was stored at 4uC till used.
Preparation and characterization of LVSCE/AMVAD
formulation
The LVSCE/AMVAD formulation was prepared aseptically,
using pyrogen-free glassware and sterile Milli-Q
R water. Empty,
small (ca 100 nm average diameter), unilamellar archaeosomes
(i.e., liposomes made from archaeal polar lipids) were prepared by
hydration of 20 mg TPL in 1.0 ml water (at room temperature), as
described previously [17]. The archaeosome suspension was
supplemented with 22.4 ml of LVSCE (0.1 mg total protein), and
the total volume was made up to 1.9 ml by adding saline. While
vigorously vortexing the LVSCE/archaeosome suspension in the
presence of 5 sterile glass beads (ca 3 mm diameter each) to aid
mixing, 0.1 ml of 1.0 M filter sterilized stock CaCl2 solution was
added in a drop-wise manner to convert the suspension into
LVSCE/AMVAD formulation, as described previously for
making OVA/AMVAD formulations [14,17]. The LVSCE/
AMVAD formulation was further vortexed for approximately
3 min to reduce the average width of .95% of the AMVAD
structures to less than 5 mm. The LVSCE/AMVAD preparation
was viewed under phase contrast microscopy (ca 12506
magnification) to verify that the typical, individual, very small,
spherical archaeosome structures (barely visible at this magnifica-
tion) in the original LVSCE/archaeosome suspension were absent
or very minimal, and had been predominantly converted into
much larger aggregates with phase bright surface perimeters
[13,17] which represent typical AMVAD structures. The appear-
ance of AMVAD formulation under phase contrast microscopy
was recorded using an Olympus Model BX51 TF microscope
(Olympus America, Melville, NY, USA) mounted with a
Micropublisher
R 5.0 RTV digital camera (QImaging, Burnaby,
British Columbia, Canada). The average width of the AMVAD
structures in the formulation was determined by randomly
measuring the widths of a minimum of 100 AMVAD structures
from the images taken above, using QCapture Pro software
(QImaging).
Based on the starting amount of the lipid used for making the
archaeosomes, the total LVSCE protein added, and amount of the
CaCl2 added to make the LVSCE/AMVAD formulation, the
ratio of antigen:lipid (w/w) was 1:200, the ratio of lipid:Ca
2+ (w/w)
was 1:5, and the CaCl2 concentration in the formulation was
50 mM.
All LVSCE/AMVAD formulations were stored at 4uC until
use. Just prior to use for each immunization, aliquots of the
AMVAD formulation were diluted to the immunization dose in a
final concentration of 0.85% saline/20 mM CaCl2 (pH 7.1).
Mice immunizations and pre-challenge sample collection
The efficacy of LVSCE/AMVAD vaccine in eliciting mucosal
and systemic immune responses, and in affording protection
against an i.n. pathogen challenge was evaluated in BALB/c mice.
Specific-pathogen-free, female BALB/c mice were purchased from
Charles Rivers Laboratories (Montreal, QC, Canada), and entered
the experiments at 6–8 weeks of age (about 18 g). Mice were
housed and used as per the Canadian Council on Animal Care
Guide to the Care and Use of Experimental Animals. This study
and all animal care/use protocols were approved (ID # 2007-15)
by the Institute for Biological Sciences (National Research Council
Canada) Animal Care Committee.
Groups of mice (n=20) were immunized intranasally (50 ml
volume) after anesthetizing with isofluorane. The mice were
immunized (0, 7 and 21 d) with LVSCE alone (in saline), LVSCE
admixed with 1.0 mg cholera toxin (LVSCE/CT, Sigma-Aldrich
Canada Ltd, Oakville, Ontario, Canada), or LVSCE/AMVAD
formulation. A fourth group consisted of naı ¨ve mice. The LVSCE
antigen dose (total protein basis) in each instance was 1 mg/
mouse/immunization. For the LVSCE/AMVAD vaccine, this
antigen dose corresponded to the inclusion of 0.2 mg of the
archaeal TPL as part of the LVSCE/AMVAD formulation.
At day 28, 5 mice per group were euthanized by CO2
asphyxiation and the sera were obtained (for anti-body assays and
cytokines) from total blood collected by cardiac puncture [13], and
the spleens were harvested (for in vitro splenocyte proliferation
assay). The lungs were lavaged 5 times with 1.0 ml PBS containing
3 mM EDTA [18] to obtain bronchoalveolar lavage (BAL) fluid. A
haemocytometer was used to count the total BAL cells. Cytospin
slides were prepared and stained with HemaStat 3
R (Fisher,
Pittsburgh, PA), and 200 cells were examined to determine the
differential cell counts. The rest of the BAL fluid was centrifuged
(2,4506g, 7 min) and the supernatant was stored at 280uC until
analyses.
ELISA for LVSCE-specific IgA, IgM, IgG and IgG isotypes
LVSCE-specific IgA, IgM, IgG1, and IgG2a antibodies were
measured by indirect enzyme-linked immunosorbent assays
(ELISA) [13]. Briefly, 96-well flat-bottom Immunolon 2
R micro-
plates (Thermo Electron Corporation, Milford, MA, USA) were
pre-coated with 0.5 mg LVSCE/well, in 100 ml of 0.1 M
bicarbonate buffer (pH 9.6). Serially diluted (2-fold increments)
samples of sera and BAL fluid, as indicated in the figures, were
used to derive the antibody titration curves.
Determination of antigen-specific splenocyte
proliferation and cytokine production
In selected experiments, the immunized and naı ¨ve mice were
sacrificed at day 28 and their spleens aseptically removed and used
to prepare single cell suspensions. Spleen cells were suspended at a
concentration of 2.5610
6 cells/ml in Dulbecco’s Modified Eagle
Medium (DMEM) containing 2 mM L-glutamine, 25 mM
HEPES, 10% fetal bovine serum, 5610
25 M 2-mercaptoethanol,
100 U of penicillin/ml, and 100 mg of streptomycin/ml, in the
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6
bacterial cells/ml), or Concanavalin A (Con A, 5 mg/ml) as the
positive control for the assay, or medium only (as the negative
control for the assay), as described previously [18]. The cells were
cultured (37uC, 5% CO2) in duplicates in 24-well (for culture
supernatant), or in triplicates in 96-well (for proliferation assay),
flat-bottom tissue culture plates. For spleen cell proliferation assay,
the cells were cultured for 90 h. At 72 h, 1 mCi of
3H-thymidine
was added to each well, and the cells were harvested at the end of
the culture period and analyzed for
3H-thymidine incorporation
using a beta-scintillation counter. Stimulation Index was calculat-
ed as [counts per minute, stimulated cells]/[counts per minute,
media-treated control cells]. For cytokine measurements, cell
culture supernatants were collected at 48 h, centrifuged, and
stored at 280uC until assay.
Cytokines/chemokines measurement
The cytokine/chemokine levels in sera, BAL fluid, and the
supernatants of lung homogenates and spleen cell cultures were
measured in duplicate, using Milliplex MAP
R mouse cytokine/
chemokine kit (Millipore, Billerica, MA, USA) and a LuminexH
100IS system (Luminex Corp., Austin, TX). The cytokine/
chemokine concentrations were calculated against the standards,
using Beadview
R software (Upstate Group LLC, Lake Placid, NY)
[19].
Intranasal challenge with F. tularensis LVS and
monitoring
At day 35 (14 day post the last immunization) mice were
anesthetized by i.p. injection of ketamine and xylazine (at 0.1 mg
and 0.05 mg/g body weight of mouse, respectively, in 0.25 ml
injectable saline) and intranasally challenged with 3.4610
4 colony
forming units (CFU) of F. tularensis LVS in 50 ml saline. In our
laboratories, the LD50 upon i.n. administration of this strain to
female BALB/c mice is ca 10
3 CFU. Each group of mice was then
split into three sub-groups of 5 mice each. In addition to the
availability of the normal sources of food and water ad labium, all
the challenged mice were given access to ‘‘Nutra-gel’’ (Bio-Serv,
Frenchtown, NJ, USA) tablets which were placed on the floors of
the cages.
The body weights of one sub-group of each of the 4 challenged
groups of mice were monitored once daily and the clinical signs
were monitored and recorded. The body weight change was
calculated as a percentage change from the pre-challenge weight.
The overall clinical sign for each mouse was scored on a sliding
scale of 0 to 5. Individual clinical scores were assigned as 0
(normal, active, healthy), 1 (slightly sick, slightly ruffled fur,
otherwise normal), 2.0 (sick, ruffled fur, slow movement,
hunching), 3.0 (very sick, ruffled fur, very slow movement,
hunched, eyes shut), 4.0 (moribund), or 5 (dead). To calculate
the average clinical score of a sub-group of mice, any mouse that
had died (or had been euthanized for humane reasons) on that day
was included in the averaging of the clinical score for that day, but
not for averaging the score on subsequent days for the surviving
mice in the group. The % of mice in each group that survived the
challenge was recorded.
Pathogen burdens and post-challenge sample analyses
At 1 and 4 days post i.n. challenge, 5 mice per each group were
euthanized and the sera were collected and assayed for cytokines/
chemokines as described above. The lungs and spleens were
homogenized in 2 ml saline and 10-fold serial dilutions were
plated on chocolate agar plates supplemented with haemoglobin,
Isovitalex
R and antibiotics [18], to determine the F. tularensis LVS
burdens in the respective organs. Remainder of the lung
homogenate was treated with CompleteH protease inhibitor
(Roche Diagnostics, Laval, QC, Canada) and the supernatant
collected (2,4506g, 7 min) for cytokine/chemokine assays as
described above.
Statistical analyses
Data are presented as means 6 SD. Differences between groups
were determined by one- or two-way analysis of variance
(ANOVA) followed by Dunnett’s multiple comparison test or
Bonferroni post test, respectively (GraphPad Prism 4.0, GraphPad
Figure 1. LVSCE/AMVAD vaccine induces strong LVSCE-specific
IgA levels in sera and BAL fluids. Groups of female BALB/c mice
(n=20) were immunized i.n. at 0, 7 and 21 d (1 mg LVSCE antigen, on
total protein basis, per mouse per immunization) with LVSCE, LVSCE/
AMVAD or LVSCE/CT. A naı ¨ve control group was also included. Five
mice per group were euthanized at 28 d, for collection of sera and BAL
fluids for LVSCE-specific IgA analyses by ELISA. Each data point
represents the mean OD 6 SD for each group. Data are representative
of two separate experiments.
doi:10.1371/journal.pone.0015574.g001
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statistically analyzed by the logrank test. Differences were
considered significant at p,0.05.
Results
Vaccine induced mucosal and systemic antibody
responses
The AMVAD system is a non-replicating mucosal adjuvant/
delivery system. Therefore, we used a vaccine adjuvanted with CT
(LVSCE/CT) as a positive control in our study, since it is
recognized as a strong, non-replicating mucosal adjuvant.
However, the toxicity of CT in humans precludes its use in
vaccines for humans. The other controls included antigen alone
(LVSCE) immunization, and naı ¨ve mice. The anti-LVSCE IgA
antibody titres measured in the sera and BAL fluids of mice
immunized with the LVSCE/AMVAD vaccine were strong and
much higher than those seen with LVSCE alone immunization or
in naı ¨ve mice (Fig. 1). As expected, the strongest responses were in
mice immunized with LVSCE/CT. The systemic immune
responses assessed as anti-LVSCE IgM and IgG1 antibody titres
in sera from mice immunized with LVSCE/AMVAD and
LVSCE/CT vaccines were strong, and generally comparable
(Fig. 2). However, the specific IgM and IgG1 responses in the BAL
fluids, and the specific IgG2a titres in sera and BAL fluids, were
the strongest in the LVSCE/CT group.
Figure 2. LVSCE/AMVAD vaccine induces strong LVSCE-specific IgM, IgG1 and IgG2a levels in sera and BAL fluids. The sera and BAL
fluids collected at 28 d from the naı ¨ve, and LVSCE, LVSCE/AMVAD or LVSCE/CT immunized groups of mice in Figure 1 were analyzed for the indicated
LVSCE-specific antibody by ELISA. Each data point represents the mean OD 6 SD for each group (n=5). Data are representative of two separate
experiments.
doi:10.1371/journal.pone.0015574.g002
Archaeal Lipid Mucosal Vaccine Efficacy
PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e15574Vaccine induced antigen-specific cellular immune
responses
To determine the antigen-specific cellular immune responses
elicited by LVSCE/AMVAD vaccine, we assessed the antigen-
specific lymphocyte proliferation response and the production of
IFN-c, IL-2, IL-4, IL-10, IL-17 and MIP-1b by the splenocytes, in
response to stimulation with formalin-fixed F. tularensis LVS. The
splenocytes from LVSCE/AMVAD-immunized mice showed
higher (but not significantly) proliferation (SI of 8.367.6),
compared to mice immunized with LVSCE alone (SI of
3.860.06), and significantly higher production of IL-10 (p,0.05)
and IL-17 (p,0.01) in response to ffLVS stimulation (Fig. 3). The
stimulation index (14.966.6) for the LVSCE/CT immunized
group was significantly higher (p,0.01 vs. LVSCE alone group).
The IL-10 and lL-17 levels in the LVSCE/AMVAD and
LVSCE/CT group were comparable (Fig. 3). Compared to the
LVSCE group, the amount of IL-2 produced by the splenocytes
from the LVSCE/AMVAD group was higher, but not signifi-
cantly as seen with LVSCE/CT group. The IL-4 responses were
below the detection limit (,10 pg/ml) in all groups of mice. It was
somewhat surprising to note that compared to the LVSCE group,
the IFN-c levels were significantly different (p,0.05) and higher in
the naı ¨ve group only. The IFN-c levels seen with splenocytes from
the LVSCE/CT and LVSCE/AMVAD groups were lower, being
similar to the LVSCE group. In response to Con A stimulation
(positive stimulation control), there were no significant differences
in the magnitude of lymphocyte proliferation (SI of 8.2–10.5) or
most of the cytokine levels (data not shown) between the different
groups of mice.
Pre-challenge BAL cellular and cytokine profiles
At day 28 (7 d post third immunization), there were significantly
higher numbers of total BAL cells and the numbers of alveolar
macrophages in BAL fluids from the LVSCE/AMVAD (p,0.05)
and LVSCE/CT (p,0.01) immunized groups, as compared to
those in the LVSCE alone immunized or the naı ¨ve groups
(Table 1). The numbers of neutrophils and lymphocytes in the
BAL fluids of the LVSCE/AMVAD and LVSCE/CT immunized
mice were also higher than in the antigen alone immunized
(LVSCE) or naı ¨ve groups, but these were significantly higher
(p,0.01) only in the LVSCE/CT immunized group. As expected,
the BAL fluid cells from naı ¨ve mice were almost entirely
comprised of macrophages (Table 1).
In the BAL fluids, we also measured the levels of a panel of 11
cytokines/chemokines that are known to be involved in the
recruitment and activation of innate and acquired immune cells.
Of these, KC (a neutrophil chemotactic factor) was significantly
higher (p,0.01) in the BAL fluids of mice immunized with
LVSCE/AMVAD (150647 pg/ml) or LVSCE/CT (256655 pg/
ml), as compared to the naı ¨ve (3468 pg/ml) or LVSCE alone
immunized (66622 pg/ml) groups. The IL-17 level was just above
the detectable limit in the LVSCE/CT group only. The IP-10
levels in the BAL fluids of the LVSCE alone (74633 pg/ml) and
LVSCE/CT (88624 pg/ml) groups were comparable, but these
were significantly lower in the LVSCE/AMVAD (30612 pg/ml)
and naı ¨ve (1668 pg/ml) groups, as compared with the LVSCE
Figure 3. LVSCE/AMVAD vaccine induces production of
cytokines by splenocytes. Splenocytes (2.5610
6 cells/ml) obtained
from the naı ¨ve, and LVSCE, LVSCE/AMVAD or LVSCE/CT immunized
mice euthanized at 28 d in Figure 1 experiment, were stimulated in vitro
for 48 h (37uC, 5% CO2) in the presence of formalin-fixed F. tularensis
LVS (ffLVS; 2610
6 cells/ml). The supernates were collected and assayed
for various cytokines. Supernates collected from the respective
splenocytes stimulated with media only were the negative controls,
and those collected from splenocytes stimulated with Concanavalin A
(data not shown) were the positive controls, respectively, for the assay.
The data are presented as mean 6 SD for each group (n=5) of naı ¨ve,
and LVSCE, LVSCE/AMVAD or LVSCE/CT immunized mice.
* p,0.05 and
** p,0.01 vs. LVSCE alone immunized group.
doi:10.1371/journal.pone.0015574.g003
Table 1. Cell populations in the bronchoalveolar lavage fluids of mice at 28 d (7 d post third immunization at 21 d).
Group Total number of cells ( 610
5) Mean number of cells ( 610
5) and % of
Macrophages Neutrophils Lymphocytes
Naı ¨ve 7.5063.31 7.3863.28 (9861%) 0.0460.05 (061%) 0.0960.02 (161%)
LVSCE 3.0361.61 2.6761.65 (8669%) 0.0960.04 (463%) 0.2360.13 (966%)
LVSCE/AMVAD 15.3866.93* 12.2465.55* (8066%) 0.7560.67 (564%) 2.3761.60 (1466%)
LVSCE/CT 41.7060.28** 26.8769.21** (6369%) 6.5860.71** (1664%) 8.2562.75** (2067%)
Data are presented as mean 6 SD.
* p,0.05 and
** p,0.01 vs. LVSCE alone immunized group.
doi:10.1371/journal.pone.0015574.t001
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IL-4, IL-6, MCP-1, RANTES or TNF-a (,10 pg/ml) in the BAL
fluid of any mouse group (data not shown).
Body weight, clinical scores and survival after i.n. F.
tularensis LVS challenge
All groups of mice lost about 10% of their pre-challenge body
weight by 4 days post the i.n. challenge with F. tularensis LVS
(Fig. 4A). At 6–7 days post-challenge, the surviving mice in the
LVSCE alone and naı ¨ve groups had lost close to 25% of their
body weight and were euthanized (humane end point in
conjunction with the clinical scores). In contrast, the LVSCE/
CT immunized mice lost about 12% of their body weight by 9
days post-challenge, and the surviving mice began to gradually
regain weight to achieve a 10% gain over the pre-challenge weight
by 22 days post-challenge. The LVSCE/AMVAD immunized
mice gradually lost weight for about 12 days post-challenge, and
after a stabilization period of about 4 more days, the surviving
mice began to regain the lost weight, achieving a gain similar to
the LVSCE/CT group.
Based on the clinical scores (Fig. 4B), the naı ¨ve and LVSCE
alone immunized mice began to get sick rapidly, and by 7–8 days
post-challenge all of the mice were either dead or had to be
euthanized due to high clinical scores and body weight loss. The
mean clinical score of the LVSCE/AMVAD group at up to 10
days post-challenge was about 1.0 or lower, indicating mild
sickness. Subsequently, the average clinical score increased to
about 1.5 by 13 days post-challenge, and the scores for the
surviving mice at that period began to stabilize and eventually
reverted to 0 (fully normal) at 17 days post-challenge and beyond.
The mice in the LVSCE/CT immunized group had a mean
clinical score of less than 1.0 over the 13 days post-challenge, and
then their health improved to achieve a clinical score of 0 at
subsequent days.
All the mice in the LVSCE alone and naı ¨ve groups had died or
had to be euthanized by day 8 post-challenge (Fig. 4C). In
contrast, 100% of the mice in the LVSCE/AMVAD and
LVSCE/CT immunized groups were alive at 12 days post-
challenge. Significantly (p,0.01), 80% of the LVSCE/CT and
20% of the LVSCE/AMVAD immunized mice survived the ca
346 LD50 i.n. challenge with F. tularensis LVS, compared to the
naı ¨ve or LVSCE immunized groups (Fig. 4C). Although a higher
percentage of the LVSCE/CT immunized group survived the
challenge compared to the LVSCE/AMVAD group, there were
no statistically significant differences between the survival curves of
these two groups.
Lung and spleen pathogen burdens at 1 and 4 days post
i.n. F. tularensis LVS challenge
To determine if the AMVAD vaccine promoted pulmonary
clearance of F. tularensis LVS and restricted the systemic
dissemination of the bacterium, quantitative bacteriology was
performed on the lungs and spleens at 1 and 4 day post-challenge.
At 1 day post-challenge, the mean pathogen burdens in the lungs of
allgroupsofmicewere comparable (Fig.5A),andthe burdens inthe
spleens were generally below the detection limit (Fig. 5B). At 4 days
post-challenge, the pathogen burdens in the lungs of LVSCE/
AMVAD (p,0.05) and LVSCE/CT (p,0.01) groups were
significantly lower (ca 0.5–1.0 log10) than those in the group
immunized with LVSCE alone (Fig. 5A). At 4 days post-challenge,
the pathogen burdens in the spleens of mice from the LVSCE/
AMVAD group werelower (ca 0.5 log10), although not significantly,
than in the LVSCE group (Fig 5B). The highest pathogen burdens
in the lungs and spleen were seen in the naı ¨ve group.
Serum and lung cytokine/chemokine profiles at 1 and 4
days post intranasal F. tularensis LVS challenge
A panel of 10 pro-inflammatory and T cell cytokines that were
previously implicated in the pathogenesis of, and protection
against, LVS infection were analyzed in the sera and lungs of mice
at 1 and 4 days post-challenge (Fig. 6). At 1 day post-challenge,
Figure 4. LVSCE/AMVAD vaccine partially protects against i.n.
F. tularensis LVS challenge. The remaining naı ¨ve, and LVSCE, LVSCE/
AMVAD or LVSCE/CT immunized groups of mice (n=15) in Figure 1
experiment, were intranasally challenged with F. tularensis LVS (3.4610
4
cfu) at 35 d (14 d post the last immunization). The % change in body
weight (A), clinical scores (B) and % survival (C) of sub-groups of 5 mice
per each group was recorded over a 22 d period subsequent to the
challenge. The data are presented as mean 6 SD for each group (n=5)
for panels A and B.
** p,0.01 vs. LVSCE alone immunized group. Data
are representative of two separate experiments.
doi:10.1371/journal.pone.0015574.g004
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MCP-1 were detected in the serum samples of all groups of mice.
The serum levels of other cytokines/chemokines in all groups were
generally below the detection limit (,10 pg/ml) at 1 day post-
challenge, with the exception of IL-4, IL-6, IL-10, IL-12, IL17,
and TNF-a in the LVSCE/CT group. The IFN-c level was below
the detection limit in all groups of mice at this time point. The
serum levels of the majority of cytokines/chemokines (except IL-4,
IL-10, and IL-12) increased dramatically at 4 days post-challenge,
and the levels of IFN-c, IL-6, IP-10 and MCP-1 were significantly
higher (p,0.01) in the naı ¨ve group as compared to the LVSCE
alone immunized group. At 4 days post-challenge, the levels of
IFN-c in the LVSCE/AMVAD and LVSCE/CT group were
significantly lower (p,0.05) than that in the LVSCE group. IL-17
was the only cytokine whose level was significantly higher
(p,0.001) in LVSCE/CT immunized group, as compared to the
LVSCE alone group (Fig. 6).
Similar to the observations in sera, the majority of cytokines/
chemokines were below the detection limit in the lung homogenates
at 1 day post-challenge, with the exception of moderate and
comparable amounts of IP-10, KC and MCP-1 detected in all
groups of mice (Fig. 6). The levels of IFN-c, IL-17, IL-6, IP-10, KC,
MCP-1and TNF-a inthe lungsof all micewere substantially higher
at 4 days post-challenge, as compared to at 1 day (Fig. 6). The levels
of IL-10 and IL-4 were at or below the detection limit (,10 pg/ml).
As in the serum, most of the BAL cytokine/chemokine levels at this
time point were higher in the naı ¨ve mice and mice immunized with
LVSCE alone, than those in mice immunized with LVSCE/CT or
LVSCE/AMVAD, with the exception of the IL-17. The level of IL-
17 was higher in the LVSCE/AMVAD group and significantly
higher (p,0.001) in the LVSCE/CT immunized group, as
compared to the LVSCE alone immunized group. There were no
significant differences in the IFN-c levels in of all groups of mice,
compared to the LVSCE alone group (Fig. 6).
Discussion
In this study, we evaluated the ability of the AMVAD system to
elicit protective immunity against mucosal infections, using a
mouse model of i.n. F. tularensis LVS challenge. Compared with
LVSCE antigen alone, the LVSCE/AMVAD vaccine induced
substantially higher mucosal and systemic antibody responses. The
LVSCE/AMVAD vaccine also induced cellular immune respons-
es, as assessed by antigen-specific lymphocyte proliferation and the
production of several T cell cytokines such as IL-17 and IL-10.
More importantly, the immune responses induced by the LVSCE/
AMVAD vaccine partially protected against a 346 LD50 i.n.
challenge with F. tularensis LVS, as judged from the substantially to
significantly reduced pathogen burdens in the lungs and spleens,
an increased mean time to death and a higher survival rate, as
compared to mice immunized with LVSCE antigen alone.
Cholera toxin was used as a positive control adjuvant in this
work since it represents one of the most potent and frequently
used experimental mucosal adjuvants [8]. The antibody responses
induced by LVSCE/AMVAD immunization were generally
robust, but the responses induced by LVSCE/CT were usually
stronger. However, the considerable toxicity of CT in humans
precludes its direct application in mucosal vaccines for humans.
Although our results demonstrated that LVSCE/AMVAD is
capable of inducing protective immune responses against a lethal
Figure 5. LVSCE/AMVAD vaccine reduces the bacterial burdens in the lungs and spleen. Five mice per naı ¨ve, and LVSCE, LVSCE/AMVAD or
LVSCE/CT immunized groups challenged with 3.4610
4 cfu of F. tularensis LVS in the Figure 4 experiment were euthanized at 1 or 4 d post-challenge,
and the F. tularenisis burden (log10 cfu/organ) in the lungs (A) and spleen (B) determined. The data are presented as mean log10 cfu 6 SD for each
group, at each time point (n=5). The dotted line represents the detection limit.
* p,0.05 and
** p,0.01 vs. LVSCE alone immunized group. Data are
representative of two separate experiments.
doi:10.1371/journal.pone.0015574.g005
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responsible for this immunity remains to be characterized. The
anti-LVSCE IgA antibody responses in the sera and BAL fluid of
the LVSCE/AMVAD and LVSCE/CT groups were much
stronger (and somewhat comparable) compared to the little
response in the LVSCE or none in the naı ¨ve group. Since the
LVSCE/AMVAD and LVSCE/CT were the only groups
showing increased time to death and partial survival upon an
i.n. F. tularensis LVS challenge, it suggests that mucosal IgA plays
some protective role in this challenge model. In this regard, it has
been recently shown by several groups that mucosal IgA is
important in host defense against infections with F. tularensis and F.
novicida [20,21,22].
Although it is generally recognized that cell-mediated immunity
(CMI) is required for protection against an infection with the more
virulent clinical type A and type B strains of F. tularensis [23], it is
less clear whether or not CMI is imperative for host defense
against infection with the less virulent F. tularensis LVS. However,
studies by several groups have previously shown that specific
antibodies or serum transfer appear to be sufficient for protection
against systemic LVS challenge [24,25,26]. The antigen-specific
IgG2a antibody titer was higher in the sera from the LVSCE/CT
immunized group, compared to that in the LVSCE/AMVAD and
LVSCE groups. Since LVSCE/CT-immunized group also had a
higher, but not significantly, survival rate against the i.n. LVS
challenge than did the LVSCE/AMVAD group, it is plausible to
speculate that in addition to the mucosal IgA, IgG2a plays a key
role in the host defense against i.n. LVS challenge. In this regard,
it is well established that IgG2a can function as an important
effector molecule in the antibacterial activities through its role in
the antibody-dependent cell-mediated cytotoxicity and comple-
ment fixation [27]. In addition, a robust IgG2a response could be
regarded as an indication of a strong induction of a Th1-biased
immune response, which in turn could play a crucial role in host
defense against F. tularensis infection. In this regard, we noted that
LVSCE/AMVAD or LVSCE/CT immunization appears to
Figure 6. Changes in cytokine/chemokine levels in the sera (two left panels) and lungs (two right panels) subsequent to challenge.
The sera and lung homogenates from naı ¨ve, and LVSCE, LVSCE/AMVAD or LVSCE/CT immunized groups of mice intranasally challenged with F.
tularensis LVS (3.4610
4 cfu) and euthanized in Figure 5 experiment at 1 and 4 d post-challenge, were analyzed for the indicated cytokines/




vs. LVSCE alone immunized group.
doi:10.1371/journal.pone.0015574.g006
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IFN-c and IP-10 by splenocytes compared to the LVSCE group,
but the LVSCE/CT group did produce significantly higher IL-2
level upon in vitro stimulation with ffLVS (Fig. 3). It should be
noted that the weaker IgG2a response seen with LVSCE/
AMVAD vaccine in this study does not suggest an inherent
deficiency of the AMVAD system, and appears to be related to the
specific LVSCE antigen, since we have seen that intranasally
administered OVA/AMVAD [13] and other antigen/AMVAD
(unpublished data) vaccines induce strong antigen-specific IgG2a
responses compared to the antigen alone groups.
To further understand the protective mechanism induced by
LVSCE/AMVAD vaccine, we compared the in vitro cytokine/
chemokine production in response to antigen stimulation of
splenocytes from mice immunized with LVSCE/AMVAD and
LVSCE alone. We found that the splenocytes from LVSCE/
AMVAD immunized mice produced significantly higher amounts
of IL-17 and IL-10 and lower amount of IFN-c in response to
ffLVS stimulation compared to the mice immunized with LVSCE
alone or naı ¨ve mice (Fig. 3). In this regard, it is interesting to note
that several groups have recently shown that endogenous IL-17
plays a crucial role in host defence against F. tularensis LVS
infection and IL-172/2 mice are incapable of controlling i.n.
LVS challenge [28,29,30]. Thus, the enhanced IL-17 production
seen in LVSCE/AMVAD and LVSCE/CT immunized mice may
partially account for their enhanced protection against the i.n. F.
tularensis LVS challenge. On the other hand, it was somewhat
surprising to note that both the LVSCE/AMVAD and LVSCE/
CT immunization appeared to have suppressed antigen-specific
IFN-c responses. However, it is possible that the high IFN-c
response seen in naı ¨ve mice (Fig. 3) was probably related to the
non-specific response to whole cell antigen preparation (ffLVS)
that we used in the assay. Although IFN-c is a key cytokine in host
defence against almost all intracellular pathogens including F.
tularensis, this cytokine has been shown to be more critical for the
control of primary rather than secondary infection with F. tularensis
LVS [31]. In addition, compared to systemic infection, IFN-c
appears to play a less crucial role in the control of F. tularensis LVS
infection via the respiratory route [32]. Thus, it is possible that
IFN-c played a marginal protective role in the current model.
We also monitored the cytokine/chemokine levels in sera and
lungs of the immunized and naı ¨ve mice after i.n. challenge with
lethal doses of F. tularensis LVS (Fig. 6). With the exception of IL-
17 which was significantly higher in the LVSCE/CT group as
compared to the naı ¨ve or LVSCE alone groups, the cytokine/
chemokine levels in both the lungs and sera were generally either
similar or lower in the more protected LVSCE/CT and LVSCE/
AMVAD groups, as compared to the naı ¨ve or LVSCE alone
group. Thus, IL-17 was the only cytokine that distinguished
between the highly protected LVSCE/CT group versus the
unprotected naı ¨ve and the LVSCE alone immunized groups.
There was little correlation between serum and lung levels of other
cytokines and the protective efficacy induced by the LVSCE/
AMVAD vaccine, and their levels seem to reflect the tissue
bacterial burdens (antigen loading) and the extent of infection.
In summary, i.n. immunization of vaccine adjuvanted with the
AMVAD system induces antigen-specific mucosal and systemic
antibody and CMI responses, and protects mice against a lethal
i.n. F. tularensis LVS challenge. The possible roles of IgA and
IgG2a antibody responses, and of IL-17, in the protective efficacy
are implied. The AMVAD system elicits long-lasting and memory
boostable mucosal and systemic immune responses [13] and
preclinical murine studies have shown it to be safe [14]. It is
possible that with further experimentation regarding the antigen
dose, antigen/adjuvant ratio, the immunization schedule, or the
use of a specific identified protective antigen, the efficacy of the
AMVAD adjuvanted vaccine in the i.n. F. tularensis LVS challenge
model could be enhanced further. The current findings warrant
additional exploration of the AMVAD system as an alternative
mucosal adjuvant/vaccine delivery technology, for developing
vaccines against mucosal pathogens.
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